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Association of interleukin-6 174G/C promoter polymorphism
with hypertension and left ventricular hypertrophy in dialysis
patients.
Background. Gene polymorphisms of proinflammatory cy-
tokines, such as interleukin-6 (IL-6) and the chemokine recep-
tor CX3CR1, have been found in association with cardiovascu-
lar disease in the general population. In dialysis patients, in
whom the prevalence of cardiovascular comorbidity is strik-
ingly high, these polymorphisms have not been investigated.
Methods. The174G/C polymorphism of the IL-6 gene and
the chemokine receptor CX3CR1 polymorphisms 249V/I and
280T/M were examined for their association with cardiovas-
cular abnormalities in a cohort of 161 patients with end-stage
renal disease (ESRD) treated by hemodialysis. Arterial blood
pressure, electrocardiogram (ECG) ischemic changes, and left
ventricular mass index (LVMI) were the parameters examined
for the association study. The control group was made up of
169 healthy subjects.
Results. We found that for both IL-6 and chemokine recep-
tor, genotype frequency and allelic distribution in both ESRD
patients and controls were comparable. The genetic association
study showed that in the whole group of dialysis patients, indi-
viduals with GC  CC genotype for the 174G/C polymor-
phism had a higher diastolic blood pressure (P  0.008) and
LVMI (P  0.026) than GG homozygotes. The prevalence of
left ventricular hypertrophy (LVH) in the former group was
58.6% vs. 39.2% in the latter (P  0.02). The same analysis
limited to diabetic patients in dialysis, showed that the preva-
lence of LVH in those with CG  CC genotype was 87.5%
vs. 36.3% in those with GG genotype (P  0.02). In diabetic
patients, lower levels of serum albumin was found in the GC 
CC genotypic group than in GG subjects; 34.63  5.18 g/L vs.
41.75  4.79 g/L (P  0.003).
Conclusion. These data demonstrate an association between
the IL-6 promoter polymorphism 174G/C and high blood
pressure and LVH in hemodialysis patients, especially those with
diabetes. The results strengthen the hypothesis that chronic
inflammation is a mechanism of cardiovascular damage in dial-
ysis patients and the role played by the IL-6 system in this
mechanism.
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An association between changes in cytokine produc-
tion and cardiovascular morbidity in uremic and nonure-
mic subjects has been suggested in several reports [1, 2].
In particular, for interleukin-6 (IL-6), where plasma lev-
els in dialytic patients have been found to be abnormally
elevated [3]. A polymorphism of the IL-6 gene (174G/C)
has been detected [4], and an association of this poly-
morphism has been found with coronary artery disease and
high blood pressure in healthy men [5]. Recently, another
component of this inflammatory system, the chemokine
receptor CX3CR1, has been studied and it has been found
that its genotype exhibits an association with suscepti-
bility to cardiovascular disease [6]. Uremic patients dis-
play an abnormal prevalence of cardiovascular disease
that cannot be fully explained by traditional risk factors,
and alternative mechanisms, specific to uremia or dialytic
treatment, have been put forward [7]. A link between
chronic inflammation and cardiovascular risk in dialysis
patients has therefore been proposed on the basis of
experimental data, and recent reports suggest that in-
creased levels of C-reactive protein predict overall car-
diovascular mortality [8]. IL-6 is a primary determinant
of hepatic production of C-reactive protein and plasma
concentrations of IL-6 vary according to the genotype of
the 174G/C polymorphism [5]. Several risk factors for
hypertension and cardiovascular disease have been pro-
posed in uremic patients, but the association of the IL-6
gene polymorphism with left ventricular hypertrophy
(LVH) has not been investigated [9]. We undertook this
association study with a dialysis cohort to ascertain whe-
ther the distribution of the polymorphism of the IL-6
gene and the chemokine receptor CX3CR1 in patients
with end-stage renal disease (ESRD) suggest any associ-
ation of these polymorphisms with cardiovascular disease.
METHODS
Study cohort
All patients (N  161) treated by hemodialysis in our
unit were enrolled in the study (Table 1). We had been
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Table 1. Characteristics of study cohort (demographic, dialytic
parameters, laboratory assessment)
Number 161
Gender Men 98; women 63
Age years 66.813.6
Body mass index kg/m2 24.84.4
Total body water L 32.34.7
Diabetics % 13.6%
Smokers % 17.3%
Blood pressurea mm Hg
Systolic 140.024.6
Diastolic 77.712.3
Mean 98.515.4
Time on hemodialysis months 76.863
Interdialytic weight gain kg 2.911.05
Kt/V 1.330.36
Serum total cholesterol mmol/L 4.931.28
Serum triglycerides mmol/L 2.131.04
Serum albumin g/L 39.24.7
Hematocrit % 33.10.4
Mean  standard deviation.
a Predialysis values on antihypertensive treatment
able to establish the cause of renal failure in 124 patients:
chronic glomerulonephritis in 43 (26.8%), vascular dis-
ease in 23 (14.3%), diabetes in 22 (13.7%), nephrolithia-
sis, tubulointerstitial nephritis in 20 (12.5%), polycystic
kidney disease in 10 (6.25%), and systemic disease [sys-
temic lupus erythematosus (SLE), myeloma, and amy-
loidosis] in 6 (3.75%). In 36 (22.5%) patients the cause
of renal failure remained undetermined. The average
weekly time spent on dialysis was 11.99  0.94 hours.
The dialysis fluid was a standard bicarbonate solu-
tion (Na 139 mmol/L, HCO3 34 mmol/L, K 2 mmol/L, Ca
1.75 mmol/L, Mg 0.75 mmol/L, Cl 108 mmol/L). Dialyzer
surface was 1.3 to 2.1 m2, according to the body surface.
Dialysis membranes were made of polysulphone in 38%,
of cuprophan in 37.5%, of AN69 in 9%, of polymethyl-
methacrylate in 7.6%, and of cellulose acetate in 6.9%.
The vascular access was an arteriovenous fistula in 154
patients. A permanent intravenous catheter was used in
the others.
Blood pressure was measured with a mercury mano-
meter [10]. Hypertension was defined as systolic blood
pressure of 140 mm Hg or greater, diastolic blood pres-
sure of 90 mm Hg or above, or taking antihypertensive
medication [11]. The average values of systolic and dia-
stolic blood pressure taken in the first 4 weeks of the
study (predialytic measurements of 12 sessions) are re-
ported here and used in the analysis. Of 101 hypertensive
subjects, 73 were on pharmacologic treatment. The fol-
lowing class of drugs were employed: -blockers (N 
9), -adrenoceptor antagonists (N  9), calcium antago-
nists (N  39), clonidine (N  27), and angiotensin-
converting enzyme (ACE) inhibitors (N  24]. Erythro-
poietin was used in 139 patients.
A standard 12-lead electrocardiogram (ECG) was
performed during the first 4 weeks of the study. Ischemic
changes in the ECG were classified according the Minne-
sota code criteria, and patients with signs of past myocar-
dial infarction were included [12].
Echocardiography was performed in a nondialysis day
about 24 hours after the dialysis session within the range
of 8 weeks from the start of the study. Echocardiographic
measurements were carried out according to the recom-
mendation of the American Society of Echocardiogra-
phy [13]. Left ventricular mass was calculated using the
Devereux formula [14]. Left ventricular hypertrophy
(LVH) was defined as a left ventricular mass indexed for
body surface area (LVMI) greater than 125 g/m2 in men
or 110 g/m2 in women. Body surface area was calculated
according to the formula of Du Bois and Du Bois.
Dry weight was assessed clinically, with the aim of en-
suring an edema-free state and a control of blood pres-
sure without symptomatic hypotension. The interdialytic
weight gain of the 11 interdialytic periods of the first
month of the study was registered and the average value
is reported and used in the study. Total body water was
estimated by the formula of Chertow et al [15] specifi-
cally devised for the dialytic population.
The control group for genetic analysis comprised 169
healthy blood donors and hospital staff comparable for
age and gender with patients (age, 61.9  16.6 years; 105
men and 64 women). In these subjects the presence of
cardiovascular disease had been ruled out by periodical
health check-up. Controls and patients were residents in
the same area and belonged to the same racial and ethnic
groups.
Laboratory measurements
Venous blood samples were collected in the morning
after an overnight fast on a mid-week dialysis day. Sev-
eral hematologic, biochemical, and hormonal measure-
ments were performed. For the present study, the follow-
ing parameters are reported: hematocrit, serum albumin,
cholesterol, high-density lipoprotein (HDL), low-density
lipoprotein (LDL), and triglycerides.
The adequacy of dialytic dose was assessed, within 30
days from the start of the study, by the measurement of
Kt/V calculated using the Daugirdas equation [16].
Genetic analysis
Polymerase chain reaction-restriction fragment length
polymorphism (PCR-RFLP) analysis. The IL-6 G/C poly-
morphism was detected by PCR amplification using
primers IL-6-1, 5-TGACTTCAGCTTTACTCTTGT-3
and IL-6-2. 5-CTGATTGGAAACCTTATTAAG-3.
PCR was performed in a total volume of 25 L [100 ng
of genomic DNA, 1U Taq Polymerase, 25 pmol of each
primer, 200 mol of each deoxynucleoside triphosphate
(dNTP), and 1.5 mmol Mg]. Thermocycling was per-
formed under the following conditions: an initial dena-
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turation at 95	C for 10 minutes followed by 35 cycles of
95	C for 45 seconds, 52	C for 45 seconds, and 72	C for
1 minute, with a final extension step at 72	C for 10 min-
utes. Six microliters of the PCR product was digested
with 10 U of the enzyme NlaIII in a 10 L volume. The
products of digestion were visualized in a 2.5% agarose
gel stained with ethidium bromide.
The CX3CR1 gene polymorphisms were identified
by the amplification of a 588 bp sequence using primers
CX3CR1F, 5-CCGAGGTCCTTCAGGAAATCT-3
and CX3CR1R, 5-TCAGCATCAGGTTCAGGAA
CTC-3. The reaction was performed in a total volume
of 25 L (100 ng of genomic DNA, 1 U Taq Polymerase,
25 pmol of each primer, 200 mol of each dNTP, and 1.5
mmol Mg). Thermocycling conditions were an initial
denaturation at 95	C for 10 minutes followed by 35 cycles
of 95	C for 45 seconds, 50	C for 45 seconds, and 72	C
for 1 minute, with a final extension step at 72	C for 10
minutes. The T280M polymorphism was identified using
the enzyme BsmBI and the V249I polymorphism was
identified using PspI406I.
Statistical analysis
Data are reported as mean standard deviation (SD)
or standard error (SE), as appropriate. The forward,
stepwise logistic regression model was used to identify
risk factors. The factors selected with this model were
analyzed for their association with the chosen parame-
ters, with odds ratio (OR) (95% CI) and chi-squared.
The univariate analysis of variance was used to detect
the difference on the means of the continuous variables,
between subjects with different polymorphisms. Adjust-
ment for covariates was done by multivariate tests. Com-
parison of adjusted means was done by appropriate tests.
The data analysis was performed using the BMDB Statis-
tical Software (release 7, Cork, Ireland).
RESULTS
Data were obtained for all but one patient, who was
not thoroughly investigated and therefore excluded from
the association study. Mean values of dialytic parameters
were within the limits of National Kidney Foundation/
Dialysis Outcomes Quality Initiative (K/DOQI) recom-
mendation [17].
Hypertension was present in 101 patients (57 men, 44
women). Diastolic blood pressure was 80.5 9.4 mm Hg
in men and 75.7  11.8 mm Hg in women (NS). Systolic
blood pressure was 143.2  20.4 mm Hg and 134.7 
24.7 mm Hg in men and women, respectively (F 5.398,
P  0.021). Diastolic blood pressure was negatively cor-
related with age (t  3.294, P  0.001).
Ischemic changes on the ECG were found in 55 pa-
tients (30 men, 25 women). At the time of study inclusion,
Table 2. Polymorphisms of interleukin-6 (IL-6) and CX3CR1
in patients and controls
Polymorphism Genotype Controls (N  169) Patients (N  161)
IL-6 (174G/C) GG 105 (59.7%) 94 (53.4%)
GC 58 (34.3%) 57 (32.4%)
CC 6 (3.5%) 10 (6.2%
280T/M MM 4 (2.3%) 1 (0.6%)
TM 35 (20.7%) 35 (21.7%)
TT 130 (76.9%) 125 (77.7%)
249V/I II 13 (7.6%) 9 (5.5%)
VI 66 (39.0%) 54 (33.5%)
VV 88 (52.0% 95 (59.1%)
the prevalence of cardiovascular events was myocardial
infarction in 17 cases (10.6%) and angina in 38 (23%).
LVMI was 146.8  47.9 g/m2 in the whole cohort,
150.9  45 g/m2 in hypertensive patients, and 138.5 
53 g/m2 in normotensive subjects (NS). LVH was present
in 47% of the examined population; in 33.3% of normo-
tensive patients and in 54.3% of hypertensive patients
(OR 2.380, CI 1.132 to 5.006; chi-squared 5.351; P 
0.02). In women, LVH was present in 40.6% (LVMI 
142.4 43.7 g/m2) and in 52.5% of men (LVMI 150.2
50.9 g/m2) (NS). In diabetic subjects, the prevalence of
LVH was 57.8% (LVMI  160.5  38.4 g/m2) and in
nondiabetic subjects, it was 45.7% (LVMI  144.6 
49.1 g/m2) (NS).
The multiple regression analysis was performed to de-
tect the variables, from a set of traditional risk factors,
with most influence on LVMI. Independent variables
were the data of all patients, LVMI was the dependent
variable. The stepwise procedure excluded the following
variables: age, time on dialysis, and diastolic blood pres-
sure. The selected predictor was systolic blood pressure
(t  2.175, P  0.031).
Genetic polymorphisms
The distribution of polymorphisms of IL-6 (174G/C)
and chemokine receptor CX3CR1(280T/M and 249V/I)
genes was comparable between patients and controls
(Table 2), and was in Hardy Weinberg equilibrium in
both groups. The test was also performed on the sub-
groups (hypertensive and diabetic patients), which were
also in accord with Hardy Weinberg.
Genetic association study
Age and time spent on dialysis were comparable be-
tween individuals with different genotypes: 67.0  13.6
years and 98.4  60.1 months, respectively, in patients
with GCCC genotype for the174G/C IL-6 polymor-
phism vs. 66.8  13.6 years and 90.8  62.7 months,
respectively, in those with the GG genotype. No associa-
tion was found between ischemic changes on the ECG
and any of the polymorphisms studied. A cardiovascular
event was recorded in 34.8% of GC  CC subjects and
in 39.1% of GG homozygotes (NS).
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Table 3. Blood pressure, left ventricular mass index (LVMI) and interleukin-6 (IL-6) polymorphism (174G/C)
Systolic blood pressure Diastolic blood pressure LVMI g/m2 LVMI g/m2
Genotypes mm Hg mm Hg (hypertensive) (all subjects)
CC  GC 142.425.0 81.211.1a 160.042.8a 155.043
GG 137.720.5 76.510.0 140.643.6 140.950.3
Mean  standard deviation.
a P 
 0.05
IL-6 polymorphism. CC homozygotes were not ana-
lyzed in the association study due to their small number,
but were combined with the GC genotype group.
Serum albumin was 38.88  4.48 g/L in patients with
GCCC genotype and 39.57 4.94 g/L in GG individu-
als (NS). In diabetic GC  CC cases, serum albumin
was 34.63  5.18 g/L vs. 41.75  4.79 g/L in GG subjects
(Bonferroni test, F  9.724, P  0.003). The body mass
index was 24.6  4.7 in CG  CC cases and 24.9  4.3
in GG patients (NS).
Patients who were GC  CC for the 174G/C poly-
morphism of IL-6 had higher diastolic blood pressure
and higher prevalence of LVH compared to those with
GG genotype (Table 3). Diastolic blood pressure, ad-
justed for age and time in dialysis, was 85.0 2.2 mm Hg
(SE) in GC  CC individuals and 76.3  1.0 mm Hg in
GG homozygotes (difference  8.7 mm Hg, 95% CI
1.211 to 12.614, P  0.018). In the 10 CC homozygotes,
diastolic blood pressure was 79.9  3.1 mm Hg (SE).
The logistic regression (forward stepwise), with LVH as
a dependent variable, and with age, gender, diabetes,
albumin, hemoglobin, interdialytic weight gain, total
body water, body mass index, blood pressure, and IL-6
genotypes, 249VI and 280TM, as covariates produced
a model with the following predictors: systolic blood
pressure (P  0.026) and GC genotype (P  0.04). The
analysis limited to the CC genotype has not been per-
formed as the small number of samples makes this statis-
tically meaningless.
The prevalence of LVH in those with GC  CC geno-
type for IL-6 was 58.6% compared to 39.2% in GG
subjects (OR 2.193; 95% CI 1.040 to 4.6414; chi-
squared  5.037; P  0.025). In hypertensive subjects,
66% of those with GC  CC genotype had LVH and
44% of GG patients (OR 2.544; 95% CI 1.086 to 5.952;
chi-squared  4.727; P  0.03). In those with the GC 
CC genotype for the IL-6 polymorphism, the mean of
LVMI adjusted for age, time on dialysis, total body wa-
ter, serum albumin, and systolic blood pressure (recog-
nized risk factors for LVH in dialysis patients) was
161.7  7.0 g/m2 (SE) compared to 139.2  6.4 g/m2 of
GG individuals, mean difference 22.49 g/m2 (95% CI
2.769 to 42.215; P  0.026).
In diabetic subjects, 40.9% had the GC  CC geno-
type, while 59.1% had the GG genotype. The distribution
was comparable with the nondiabetics, 41.8% and
58.1%, respectively. The prevalence of LVH was 87.5%
in the GC  CC group and 36.3% in those with the GG
genotype (OR 2.406; 95% CI 1.055 to 5.488; chi-squared
4.968; P  0.026).
The analysis of the chemokine receptor polymor-
phisms (280M/T and 249V/I) showed no association be-
tween the individual polymorphsms and blood pressure
or LVMI. Smoking habit, gender, body mass index, Kt/V,
and type of dialytic membrane were analyzed together
with polymorphism in the association study and were
found to have no effect on hypertension or LVH.
DISCUSSION
We found that the distribution of the polymorphisms
of IL-6 and chemokine receptor CXCR1 in a cohort
of unselected patients undergoing hemodialysis was not
different from a control group of healthy subjects. The
novel finding of this study is that patients with GC 
CC genotype for the174G/C polymorphism of the IL-6
gene had higher diastolic blood pressure and LVMI than
subjects with the GG genotype. Together with hyperten-
sion, the C allele was a predictor of LVH. In diabetic
patients, the C allele was also associated with lower se-
rum concentration of albumin.
The small number of CC homozygote subjects has
hampered the study of any association of this group with
the above conditions, allowing conclusions only on the
GC genotype. We are also aware that these findings
come from a secondary analysis and therefore must be
taken cautiously.
IL-6 is a circulating cytokine secreted by macrophages,
lymphocytes, fibroblasts, adipocytes, and endothelial
cells, in response to different types of inflammatory stim-
uli. IL-6 induces endothelial damage, stimulating the in-
tracellular adhesion molecule-1 (ICAM-1) and enhanc-
ing the attachment and migration of leucocytes across
the endothelial surface [18]. A clinical confirmation of
this vascular effect comes from a very recent study in
uremic patients where an association between increased
levels of IL-6, Chlamydia pneumoniae seropositivity and
progressive carotid artery stenosis has been found [19].
Also, hypertension may increase the risk of atheroscle-
rosis via proinflammatory effects mediated by IL-6. A
recent study in apparently healthy men found a strong
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relationship between plasma levels of IL-6 and systolic
and diastolic blood pressures [20].
The up-regulation of IL-6 found in dialysis patients is
regarded as an important cause of morbidity and mortal-
ity, and has stimulated several investigations [21]. In
most studies, IL-6 plasma levels have been found to be
increased in ESRD patients treated with dialysis, while
in a minority of patients normal or reduced values have
been found [22, 23].
These variable results were first ascribed to technical
problems and to the complex regulatory system of cyto-
kines [24]. More recently, genetic studies have shown
that a polymorphism in the promoter region of the IL-6
gene, a G/C change in position 174, influences plasma
levels of IL-6 [5]. A gene-environment interaction has
therefore been proposed to explain the blunted or the en-
hanced IL-6–mediated acute phase response, expressed
by reduced or raised concentrations of IL-6 in different
subjects and in different pathologic conditions. In healthy
subjects, the C allele of the –174G/C polymorphism was
associated with lower plasma levels of IL-6 [25]. Data
on plasma IL-6 levels and 174G/C polymorphism in
dialysis patients have not been reported in the literature.
Patients undergoing coronary artery bypass graft surgery
had comparable baseline IL-6 levels across different IL-6
genotypes, but, after the procedure, the rise in IL-6 was
greater in carriers of the CC genotype than in carriers
of the G allele [26]. In the general population, the C al-
lele is associated with higher levels of C-reactive protein
whose gene expression is regulated by IL-6 [27]. These
finding points to a difference in IL-6 production in re-
sponse to pathologic stimuli that is genetically determined.
A possible confounding factor in our study was a sur-
vival effect. Although we believe that analysis of age and
time on dialysis for individuals with different genotypes
makes this an unlikely explanation, it cannot be definitely
excluded. Furthermore, in our patients, the overall distri-
bution of the IL-6 polymorphism was comparable with
the control group. However, the different distribution
of alleles within patient subgroups suggests a possible
contributory role of IL-6 in some of the comorbid condi-
tions found in dialysis patients. Hypertension has already
been found in association with high levels of markers of
inflammation such as IL-6 and ICAM-1 in otherwise
healthy people, but not in renal patients [21]. Further-
more, a recent genetic association study suggested that
the effect of the IL-6 174G/C polymorphism on blood
pressure is likely to be operating through an inflamma-
tory pathway, more probably mediated by a local and not
systemic production of IL-6 [5]. IL-6 is able to stimulate
the central nervous system and the sympathetic nervous
system, which may result in hypertension [28]. In rats
treated with NG-nitro-l-arginine methyl ester (L-NAME),
hypertension was associated with increased expression
of IL-6 in the vascular wall, the molecular plasticity of
which was altered [29]. Of more clinical impact, and with
some reference to our diabetic patients, is the recent
report that has shown an association of IL-6 with insulin
resistance and with hypertension in apparently healthy
subjects [30]. Dialysis patients, in whom we found an
association between this polymorphism and raised dia-
stolic blood pressure, have several predisposing fac-
torsthat may lead to activation of the inflammatory sys-
tem, and these could act in synergy with the genotype.
The inflammation-associated vascular damage in uremic
patients has been well demonstrated [31]. The associa-
tion of LVH with homocysteine concentration in ESRD
raises the possibility of a connection between vascular
damage and LVH [32]. The link between endothelial dys-
function and cardiac hypertrophy has been shown in un-
treated hypertensives in whom the drug-induced vasodi-
lation was inversely correlated with the LVMI [33]. A
suggestion that IL-6 may play a role in this complex
mechanism comes from our finding of reduced albumin
in diabetic patients with GC CC genotype. The associ-
ation of high IL-6 with reduced levels of albumin in dialysis
patients is known to predict mortality in hemodialysis pa-
tients [34]. From the low levels of albumin in those with
the GC  CC genotype, we can infer high IL-6 levels
associated with this polymorphism. IL-6 also acts at the
tissue level. In the experimental animal with early ath-
erosclerosis, an increased expression of this cytokine in
the fibrous plaque has been observed [35]. This indirect
mechanism, mediated by endothelial dysfunction, may
interact with a more direct effect of IL-6 on the myocar-
dium, as has been shown in the experimental animal.
One phenotypic characteristic of transgenic mice over
expressing IL-6 and IL-6 receptor, is hypertrophy in adult
myocardium, suggesting that IL-6–related cytokines reg-
ulate heart muscle cells and induce cardiac hypertrophy
[36]. A new cytokine, cardiotrophin 1, with a structure
closely related to IL-6, has been cloned, and the mRNA
is expressed in the heart. This cytokine induces hypertro-
phy of cardiomyocytes [37]. These experimental findings
also suggest that tissue IL-6, in addition to the circulating
cytokine, may act on uremic heart cells in combination
with hypertension and other factors, inducing LVH.
The combined effect of different polymorphisms, with
putative inflammatory properties, has been studied in
patients with asymptomatic carotid artery atherosclero-
sis. Subjects, homozygous for two polymorphisms, 174G
of IL-6 and 6A of stromelysin-1, had an intima-media
thickness in the carotid bifurcation greater than men who
were homozygous for neither allele [38]. Finally, indirect
support for our findings comes from the recent report of
a protective effect from cardiovascular events of anti-
inflammatory IL-10 genotype in dialysis patients [39].
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CONCLUSION
Our results suggest that a genetic polymorphism of
IL-6 is associated with high blood pressure and LVH in
dialytic patients who also carry other risk factors for such
complications. These results also support a role of the
IL-6 system in the cardiovascular morbidity in ESRD
[40]. The limitations of our study lie on the relatively
small number of patients examined. Nonetheless, the
results obtained are in line with the theory of chronic
inflammation in dialytic patients and could stimulate
larger prospective studies.
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